Korea Investment CORP Acquires Shares of 72,864 Natera, Inc. $NTRA

Korea Investment CORP bought a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 72,864 shares of the medical research company's stock, valued at approximately $19,779,000. Korea Investment CORP owned approximately 0.05% of Natera at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. purchased a new position in Natera during the 2nd quarter valued at about $2,962,770,000. Coatue Management LLC grew its holdings in Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock worth $603,270,000 after purchasing an additional 2,463,008 shares during the period. Wellington Management Group LLP increased its stake in shares of Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares in the last quarter. Norges Bank purchased a new position in shares of Natera during the fourth quarter valued at approximately $372,398,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Stock Performance

Shares of NTRA stock opened at $332.03 on Monday. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $333.56. The stock has a market capitalization of $47.86 billion, a P/E ratio of -244.14 and a beta of 1.51. The firm's 50 day moving average is $274.24 and its 200 day moving average is $229.38.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company's quarterly revenue was up 37.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.74) EPS. As a group, equities analysts predict that Natera, Inc. will post -1.02 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on NTRA. Guggenheim upped their price target on Natera from $290.00 to $360.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Natera in a report on Friday, July 17th. Leerink Partners set a $330.00 price target on Natera in a report on Friday, August 7th. Zacks Research upgraded Natera from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 12th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $355.00 price target on shares of Natera in a research report on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $319.38.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 3,076 shares of the firm's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $266.39, for a total value of $819,415.64. Following the transaction, the chief executive officer directly owned 99,897 shares of the company's stock, valued at approximately $26,611,561.83. This trade represents a 2.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,410 shares of the firm's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the transaction, the insider directly owned 129,019 shares in the company, valued at $34,264,866.02. The trade was a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 181,045 shares of company stock worth $41,330,968. 5.05% of the stock is currently owned by insiders.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source